How the University of California Is Fighting a Proxy Patent Battle for an Expensive Cancer Drug in India

New Delhi: The university appears to be representing pharmaceutical companies Pfizer, Medivation and Astellas in its patent battle. They aren’t telling the Delhi high court this, but they do talk about it in other documents.



RCEP: New Zealand Negotiator at Asia Trade Pact Talks Says Countries Should Analyse TRIPS-Plus

New Delhi: I reported a series of stories on the RCEP trade negotiations, including the round of talks which India hosted in July 2017.

26 July 2017
“Civil Society Group Boycotts RCEP Consultation, Calls for Parliament Debate on Trade Deal”
Worried about the impact of the trade negotiations, a consortium of civil groups called the People’s Resistance Forum has asked for the talks to be called off.

28 July 2017
“New Zealand Negotiator at Asia Trade Pact Talks Says Countries Should Analyse TRIPS-Plus”
The negotiator’s comments were non-committal but indicated that for now, the RCEP talks have not yet moved decisively into a TRIP-plus scenario.

24 October 2017
“India Will Not Cross Red Lines on Generic Drugs in RCEP, but Stay Vigilant, Say Officials”
Healthcare watchers are calling on India to resist the free trade agreement’s provisions which could compromise India’s ability to keep supplying cheaper generic drugs to the world.

Keep Off Indian Drug Patents Law, US Lawmakers Who Lobbied Modi Are Told

New Delhi: In their letter, many individuals and organisations stated that a country with as much poverty as India should not enforce patents on drugs and vaccines the same way industrialised countries have.